Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.

David’s blood pressure was dangerously high until he received specialized care and renal denervation at BIDMC’s Complex ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

The system is developed under the leadership of Seoul National University Hospital professor Chang-Wook Jeong.

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

SAN FRANCISCO -- The investigational selective glucocorticoid receptor modulator relacorilant led to improvements in blood pressure, fasting glucose, and weight for patients with adrenal ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

CVRx, Inc. (NASDAQ: CVRX) ('CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare ...

B vitamins play a key role in managing homocysteine and supporting heart health. Based on this study, Vitamin B could be a ...